Infectious Diseases

Following is a digest of pharmacogenomics journal articles pertaining to infectious diseases. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.


Article Citation & PubMed LinkTypeMonthSNP•its Study Summary
Lamoureux F et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 2016;47:124-31.Retrospective Analysis2016-02
Wiegand SB et al. Performance and value of IFN-Lambda3 and IFN-Lambda4 genotyping in patients with chronic hepatitis C (CHC) Genotype 2/3 in a real world setting. PLoS One. 2015;10:e0145622.Cross Sectional2015-12
Teusink A et al. Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:482-6.Descriptive2015-11
Gammal RS et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2015 Sep 29 [Epub ahead of print].Review2015-09
Abidi MZ et al. CYP2C19*17 genetic polymorphism-an uncommon cause of voriconazole treatment failure. Diagn Microbiol Infect Dis. 2015;83:46-8.Case Report2015-09
Bennis Y et al. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. Br J Clin Pharmacol. 2015 Jul 2 [Epub ahead of print].Letter2015-07
Calisti G et al. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. Springerplus. 2015;4:357.Cohort2015-07
Bonora S et al. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J Antimicrob Chemother. 2015 Jul 14 [Epub ahead of print].Double-Blind, Randomized, controlled, pilot study2015-07
Elewa H et al. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 2015 Jun 13 [Epub ahead of print].Review2015-06
Chawla PK et al. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. Int J Clin Pharm. 2015 May 30 [Epub ahead of print].Retrospective Cohort2015-05
Avihingsanon A et al. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr. 2015;69:e36–7.Letter2015-05
Tangamornsuksan W et al. Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2015;18:68–76.Meta-analysis2015-04
Sousa-Pinto B et al. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01. J All Clin Immunol. 2015 Apr 28 [Epub ahead of print].Meta-analysis2015-04
Cariani E et al. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015 Apr 28 [Epub ahead of print].Meta-analysis2015-04
Sirirungsi W et al. No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults. J Acquir Immune Defic Syndr. 2015;68:e56–59.PK/PD2015-04
Parungao JM et al. Genetics and hepatitis C: It’s good to be ‘CC’. Cleve Clin J Med. 2015;82:97–104.Review2015-04
Hu C-C et al. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis. 2015;15:156.Case Control2015-04
Dhoro M et al. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol. 2015;16:4.PK/PD2015-04
Haas DW et al. Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities. Curr Opin HIV AIDS. 2015;10:116–22.Review2015-03
Luetkemeyer AF et al. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based anti-tuberculosis therapy in the STRIDE study. Clin Infect Dis. 2015;60:1860-3.PK/PD2015-02
Gautier-Veyret E et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of CYP450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother. 2015;59:2305-14.PK/PD2015-02
Avihingsanon A et al. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinaemia. J Acquir Immune Defic Syndr. 2015 Jan 23 [Epub ahead of print].Prospective cohort2015-01
Trubiano JA et al. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. J Antimicrob Chemother. 2015 Jan 3 [Epub ahead of print].Prospective pilot study2015-01
Chau MM et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014;44:1364–88.Consensus guidelines2014-12 New antifungal guidelines highlight CYP2C19 testing for voriconazole
Colic A et al. Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. Drug Metab Rev. 2014;1–13.Review2014-11
Kapoor R et al. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet Genomics. 2014 Nov 28 [Epub ahead of print].Cost-effective analysis2014-11
Berno G et al. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of lopinavir/ritonavir (LPV/r) monotherapy in HIV-1 patients. J Int AIDS Soc. 2014;17:19589.Prospective cohort2014-11
Probst M et al. IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma. PLoS ONE. 2014;9:e112613.Retrospective Cohort2014-11
López Aspiroz E et al. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman. Clin Drug Investig. 2014 Nov 13 [Epub ahead of print].Case Report2014-11
Aung AK et al. Pharmacogenomics of antimicrobial agents. Pharmacogenomics. 2014;15:1903–30.Review2014-11
Susser S et al. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS ONE. 2014;9:e112592.Retrospective Cohort2014-11
Arrieta-Bolaños E et al. The frequency of HLA-B(*)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. Hum Immunol. 2014 Oct 5 [Epub ahead of print].Descriptive2014-10
Rosso C et al. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World J Gastroenterol. 2014;20:13146–52.Retrospective Cohort2014-10
Dong ZX et al. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in Chinese Han population. J Dig Dis. 2014 Oct 14 [Epub ahead of print].Case-Control2014-10
Alculumbre S et al. IFNL3 expression and response to treatment: behind the HCV tricks. J Hepatol. 2014;61:944–6.Commentary2014-10
Gengiah TN et al. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. Antivir Ther. 2014 Oct 15 [Epub ahead of print].PK/PD Study2014-10
Trinks J et al. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med. 2014;7:339–47.Review2014-10
Yilmaz E et al. Effects of polymorphisms in interferon ? 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection. Clin Gastroenterol Hepatol. 2014;12:1753–8.Cross Sectional2014-10
Dolton MJ et al. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Curr Opin Inf Dis. 2014 Sep [Epub ahead of print].Review2014-09 
Bock JA et al. Cost-Effectiveness of IL28?Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection. Public Health Genomics. 2014; [Epub ahead of print].Cost-effective analysis 2014-09 
Baietto L et al. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. J Antimicrob Chemother. 2014 Sep [Epub ahead of print].Research letter2014-09 
Takahashi T. Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol. 2014;20:12026-30.Review2014-09 
Shakado S et al. Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. Hepatol Res. 2014;44:983-92.Retrospective cohort2014-09 
Monaghan KG et al. Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3. J Interferon Cytokine Res. 2014 Oct 24 [Epub ahead of print].Retrospective Cohort2014-09
Akkarathamrongin S et al. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol. 2014;86:1482-90.Retrospective cohort2014-09 
Eslam M et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol. 2014;61:235-41.Prospective cohort study2014-08 
Bouatou Y et al. Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYPCYP2C19 activity. AIDS Res Ther. 2014;11:25.Case report

 
2014-08 
Indolfi G, et al. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: From adults to children. World J Gastroenterol. 2014;20:9245-52. Review2014-07 
Owusu Obeng A et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014;34:703-18.Review2014-07
Baietto L et al. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab. 2014; [Epub ahead of print]. Review2014-06 
Martin MA et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95:499-500. Guidelines2014-06 
Hicks JK et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYPCYP2C19 diplotypes. Pharmacogenomics. 2014;15:1065–78.PK/PD2014-06 
Nagaoki Y et al. IFNL4 polymorphism affects on outcome of telaprevir, peg-interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol Res. 2014 Apr 2. [Epub ahead of print]. Prospective cohort study2014-04 
Yilmaz E et al. Effects of Polymorphisms in Interferon Lambda 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection. Clin Gastroenterol Hepatol. 2014;S1542-3565(14)00313-9.Retrospective cohort study2014-04 
Tipu I, et al. The IFN-? Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. Hepat Mon. 2014;14:1-13. PubMed ID: 24734091Cohort study2014-04 
 Trubiano JA et al. Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. Mycoses. 2014;57:572-6.Case report2014-04 
Michaud V et al. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 2014;14: 151-9. Sequential dose, open label, PK2014-03 
Kwara A et al. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy. 2014;34:265–71.Randomized Cross-Over Study2014-03
Ochi H et al. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in Japanese population. J Gen Virol. 2014 [Epub ahead of print] PubMed ID: 24646752Cross-sectional2014-03 
De Re V, et al. Impact of Immunogenetic IL28B Polymoprhism on Natural Outcome of HCV Infection. BioMed Research International.2014 [Epub ahead of print] PubMed ID: 24707497Review2014-03 
Zonios D et al. Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype. J Infect Dis. 2014 [Epub ahead of print]. Prospective cohort2014-03 
Liu T et al. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One. 2014;9(3):e91316.Meta-Analysis2014-03 
Aminkeng F et al. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J. 2014;14(2):160-70. Population prevalence2014-03